Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Ustekinumab success in refractory Crohn’s disease
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes.
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.
The challenge of comorbidity in clinical trials for multiple sclerosis.
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
Daclizumab Therapy for Multiple Sclerosis.
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.
Development of cladribine at Scripps for hairy cell leukemia and current results.
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Vitamin D receptor-retinoid X receptor heterodimer signaling regulates oligodendrocyte progenitor cell differentiation.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.

Pages